AI
Monday, January 13, 2014 6:23:33 PM
Alex...where were you...we missed another one...
Dec. 22nd...Rexahn has established a huge pipeline of oncology drugs that may change the way cancers are treated in the future. There is a variety of compounds to limit the risk profile of the company, and allow investors to establish some type of speculative position. We see potential upside of at least 300% rise in share price in the coming year.
There are many biotechs out there that attempt to create new molecules for the treatment of today's deadliest forms of cancer. With the speculative nature of these oncology biotechs brings some massive speculation with overblown share prices. Despite this there is one company that has been undervalued in the oncology space for the longest time trading currently at $0.43 per share.
Jan 9th...NEW YORK (AP) -- Shares of Rexahn Pharmaceuticals rose Thursday after an analyst said the company has found a good path forward.
THE SPARK: Roth Capital Markets analyst Joe Pantiginis started coverage of Rexahn with a "Buy" rating and a price target of $3 per share. He applauded the company's decision to focus on cancer drugs and said that after a couple of years in transition, Rexahn is at the start of an important year when it could report key data on several drug candidates.
RNN
Dec. 22nd...Rexahn has established a huge pipeline of oncology drugs that may change the way cancers are treated in the future. There is a variety of compounds to limit the risk profile of the company, and allow investors to establish some type of speculative position. We see potential upside of at least 300% rise in share price in the coming year.
There are many biotechs out there that attempt to create new molecules for the treatment of today's deadliest forms of cancer. With the speculative nature of these oncology biotechs brings some massive speculation with overblown share prices. Despite this there is one company that has been undervalued in the oncology space for the longest time trading currently at $0.43 per share.
Jan 9th...NEW YORK (AP) -- Shares of Rexahn Pharmaceuticals rose Thursday after an analyst said the company has found a good path forward.
THE SPARK: Roth Capital Markets analyst Joe Pantiginis started coverage of Rexahn with a "Buy" rating and a price target of $3 per share. He applauded the company's decision to focus on cancer drugs and said that after a couple of years in transition, Rexahn is at the start of an important year when it could report key data on several drug candidates.
RNN
“A man cannot directly choose his circumstances, but he can
choose his thoughts, and so indirectly, yet surely, shape his
circumstances. James Allen, As a Man Thinketh
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
